Samsung Life Insurance Launches Revised "Samsung The First Health Insurance S"

Strengthened Integrated Coverage from Testing to Treatment
Expanded Integrated Treatment Costs for Cancer and Circulatory Diseases
Coverage Extended to Non-Reimbursable Cancer Treatments such as Radioligand Therapy

Samsung Life Insurance announced on the 9th that it will revise and launch Samsung The First Health Insurance S, enhancing coverage so that customers can prepare for treatment processes for cancer and major circulatory diseases.

On the 9th, Samsung Life Insurance revised and launched "Samsung The First Health Insurance S," strengthening coverage to prepare for the treatment process of cancer and major cardiovascular diseases.

This product, launched last year, is characterized by the "Family Combination Discount," which offers premium discounts when family members enroll together and meet certain requirements, and the "Claim-Free Customer Contract Conversion" system, under which premiums are reduced if the customer's health condition improves. Based on these features, it has attracted strong interest from customers as one of Samsung Life Insurance's flagship comprehensive health products. The revised version to be launched on the 10th has strengthened its competitiveness by expanding integrated treatment cost coverage and coverage for the latest medical technologies.

Samsung The First Health Insurance S integrates key coverage needed for cancer and major circulatory disease treatment into a single structure. First, Samsung Life Insurance has newly introduced the rider "Integrated Cancer Treatment (General Hospital or Above) Rider AT," which covers treatment costs incurred at medical institutions that are general hospitals or higher, within the annual insured amount limit, so that customers can prepare for the entire treatment process, including imaging and precision tests, surgery, anti-cancer drug therapy, radiation therapy, pain relief treatment, and rehabilitation treatment.

In addition, through the "Full Out-of-Pocket (Including Non-Reimbursable) Integrated Cancer Treatment (General Hospital or Above) Rider AT," customers can prepare even for non-reimbursable areas such as robot-assisted surgery, certain targeted and immuno-oncology treatments, and proton radiation therapy, where the entire cost is borne by the patient. At the same time, in order to reduce the burden of treatment costs for circulatory diseases such as cerebrovascular and heart diseases, Samsung Life Insurance has also prepared the "Integrated Major Circulatory Disease Treatment (General Hospital or Above) Rider AT," which covers surgery, thrombolytic therapy, reimbursable thrombectomy, intensive care unit treatment, and rehabilitation treatment.

Recently, in the field of cancer treatment, targeted therapies that precisely attack cancer cells have been expanding. In particular, new medical technologies such as "radioligand therapy," which uses radioactive isotopes, are being rapidly introduced. However, many of these treatments fall under non-reimbursable items, and treatment costs are often very high. In response, Samsung Life Insurance has newly introduced the "Targeted Anti-Cancer Drug and Certain Targeted Radiation-Approved Therapy Rider" to alleviate the financial burden associated with high-cost, non-reimbursable anti-cancer treatments.

Customers between the ages of 15 and 75 can enroll in this product, and they can choose a premium payment period of 10, 15, 20, or 30 years.